http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Association of 20 potential ATP2B1‐interacting genes with blood pressure in Koreans
Kyung‐Won Hong,Hyun‐Seok Jin,Ji‐Eun Lim,Bermseok Oh 한국유전학회 2011 Genes & Genomics Vol.33 No.3
Plasma membrane calcium‐transporting ATPase 1 (ATP2B1)is associated significantly with blood pressure in Caucasians and Asians. ATP2B1 regulates calcium homeostasis and belongs to the P‐type calcium pump family; several studies have identified diverse proteins that bind to ATP2B1. We hypothesized that ATP2B1 regulates blood pressure through ATP2B1‐interacting genes. To this end, 20 potential ATP2B1‐interacting genes were selected, 197 SNPs of which were analyzed for their association of systolic and diastolic blood pressure. These 20 genes were categorized into 2 groups: ATP2B1‐binding genes and ATP2B1‐cleaving calpain family members. Three ATP2B1‐binding genes (CALM1, NOS1, and PDLIM1)were associated with blood pressure, and a SNP in CALM1(rs2401887) generated the strongest association signal (beta=‐3.60±0.92, p=8.9×10^(‐5) for systolic blood pressure and beta=‐1.40±0.62, p=0.02 for diastolic blood pressure). Of the calpain family members, 3 genes (CAPN6, CAPN9, and CAPN10)were associated with blood pressure, and the CAPN10 SNP rs4676348 yielded the strongest association signal (beta=‐0.88±0.27, p=0.001 for systolic blood pressure and beta=‐0.58±0.18, p=0.015 for diastolic blood pressure). Further, the interaction of CALM1 to ATP2B1 was examined using the blood pressure of individuals who carried both variants of CALM1and ATP2B1 genes. Similarly the interaction of CAPN10 to ATP2B1 was also examined. The CALM1 variant (rs2401887)and CAPN10 variants (rs4676348) appear to decrease blood pressure further in addition to the decrease by the variant (rs17249754) of ATP2B1, which suggests that ATP2B1 might regulate blood pressure through the ATP2B1‐interacting genes CALM1 and CAPN10.
진심통(眞心痛)에 관(關)한 문헌적(文獻的) 고찰(考察)
전찬용,조기호,이원철,김영석,배형섭,이경섭,구본홍,Jun, Chan-Yong,Jo, Ki-Ho,Lee, Won-Chol,金永錫, Yong-Seok,Bhae, Hyung-Sup,Lee, Kyung-Sup,Goo, Bon-Hong 대한한방내과학회 1990 大韓韓方內科學會誌 Vol.11 No.1
The true heartache is a condition of severe heartache corresponding to angina pectoris, as recorded from Hwang Jae Nai Kyung. According to the literatural study of true heartache, some results can be acquired, such as follows. 1. The site of the true Heartache, can be divided into two categories, first, its superficial and conscious area is the chest as same as the other heartache. But its inner lesion is the Heart-Meridian as others occupied at the Pericardium-Meridian in stead of the Heart-Meridian. 2. The etiological classification of true heartache, are Cold-evil, Heat-evil, Wind-evil, Blood stasis etc. But its major factor is Cold-evil, more than anything else. 3. The symptomatic signs of true heartache, consist of cyanotic change from hands and feet to phalanges; severe heartache pale complexion with cold breathing and its extreme state can manifestate unceased sweating called as Yang exhaustion.
Kyung-Ha Kim,Ki-Ju Jeung,Hyun-Jung Kim,Sang-Byung Bae,Chan-Kyu Kim,Nam-Su Lee,Kyu-Taek Lee,박성규,Jong-Ho Won,Dae-Sik Hong,Hee-Sook Park 대한암학회 2007 Cancer Research and Treatment Vol.39 No.2
Purpose: Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer.Materials and Methods: Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 on day 1, and this was repeated every 3 weeks until disease progression.Results: 32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2~48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3~8.5). The median time to progression was 4.7 months (95% CI: 3.1~6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%).Conclusion: Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted. (Cancer Res Treat. 2007;39:49-53)
Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma
Hong, Eun Kyoung,Choi, Seung Hong,Shin, Dong Jae,Jo, Sang Won,Yoo, Roh-Eul,Kang, Koung Mi,Yun, Tae Jin,Kim, Ji-Hoon,Sohn, Chul-Ho,Park, Sung-Hye,Won, Jae-Kyung,Kim, Tae Min,Park, Chul-Kee,Kim, Il Han Springer-Verlag 2018 EUROPEAN RADIOLOGY Vol.28 No.10
Hong, Soon Jun,Jeong, Han Saem,Ahn, Jeong Cheon,Cha, Dong-Hun,Won, Kyung Heon,Kim, Weon,Cho, Sang Kyoon,Kim, Seok-Yeon,Yoo, Byung-Su,Sung, Ki Chul,Rha, Seung-Woon,Shin, Joon-Han,Han, Kyoo Rok,Chung, W Elsevier 2018 Clinical therapeutics Vol.40 No.2
<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.</P> <P><B>Methods</B></P> <P>I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients with hypercholesterolemia who required medical treatment according to National Cholesterol Education Program Adult Treatment Panel III guidelines were eligible for participation in the study. Patients were randomly assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg in a 1:1:1:1:1:1 ratio. The primary end point was the difference in the mean percent change from baseline in LDL-C level after 8 weeks of treatment between the ezetimibe/rosuvastatin and rosuvastatin treatment groups. All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.</P> <P><B>Findings</B></P> <P>Of 396 patients, 389 with efficacy data were analyzed. Baseline characteristics among 6 groups were similar. After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were –57.0% (2.1%) and –44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (<I>P</I> < 0.001). The LDL-C–lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The mean percent change in LDL-C level in all ezetimibe/rosuvastatin combination groups was >50%. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (<I>P</I> < 0.001). There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups.</P> <P><B>Implications</B></P> <P>Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.</P>
Hong Pil Hwang,Hee Chul Yu,Kyung Pyo Kang,Won Kim,박성광,Jeong Sang Ku,Hyeongwan Kim,Sik Lee 대한이식학회 2019 Korean Journal of Transplantation Vol.33 No.3
Human immunodeficiency virus (HIV) infection was traditionally considered an absolute contraindication for transplantation because of concerns about HIV disease progression due to immunosuppression. Since potent antiretroviral therapies (ARTs) have become widely available, the prognosis of HIV-infected kidney transplant recipients has dramatically improved. Recent results of prospective multicenter trials on kidney transplantation (KT) in HIV-positive candidates have demonstrated the success and challenges of transplantation in this population. Several studies have reported comparable patient and graft outcomes between HIV-infected and HIV-uninfected recipients after KT in the era of potent combined ARTs. We report two cases of HIV-infected patients who underwent KT at our hospital. In this paper, we present a detailed report of two cases and provide a short review of the existing literature.
Kyung-Shin Choi(최경신),Ji-Han Lee(이지한),Ji-Ung Hong(홍지웅),Won-Jee Chung(정원지) 한국기계가공학회 2020 한국기계가공학회지 Vol.19 No.7
Container vessels continue to grow in size, led by global shipowner. Large ships can be loaded more cargo at a time, reducing the cost of transportation per teu. this eventually leads to economies of sale, in which the production cost per unit decreases with increasing output. in accordance with the 70th Convention of the Marine Environment Protection Committee of the International Maritime Organization, as of January 1, 2020, MARPOL Annex Ⅵ Regulation 14.1.3 will be effective. All vessels must be meet these criteria to reduce Sox emissions and reduce NOx emissions by reducing the content of manned sulfur oxides from 3.5% to less than 0.5%, otherwise IACS Member States Entry to the port is denied. in order to do that need to LNG storage tank. in this study characteristic of the material after line heating (600℃,700℃,800℃,900℃) of 9% Ni steel used in the manufacture of LNG fuel tank of ship were verified using by mechanical test. In the heating method by line heating. The initial properties of steel are changed by variables such as temperature, time, speed. The experimental data of line heating presented in this paper confirmed that the initial change of 9% Ni steel could be minimized.
Hirayama Disease with Isolated Spinal Cord Atrophy
Kyung-won Lee,Taewon Kim,Seong-Hoon Kim,Yun Jeong Hong,Jae Young An 대한신경초음파학회 2023 대한신경초음파학회지 (JNN) Vol.15 No.2
This report presents a young-aged man with Hirayama disease who had muscle atrophy and weakness strictly confined to the C8/T1 myotome that consistently accorded with electromyographic results. In the magnetic resonance imaging (MRI) evaluation, there was only a prominent isolated spinal cord atrophy without any typical flexion MRI features of Hirayama disease. We speculate that it may be possible to have only isolated spinal cord atrophy as a limited form in Hirayama disease even in the absence of anterior displacement of the dura in the flexed position. These findings emphasize the importance of understanding both typical and atypical limited findings of the MRI imaging features of Hirayama disease, because it’s critical to distinguish Hirayama disease, mostly showing benign course, from fatal conditions like amyotrophic lateral sclerosis.